Leland Stanford Junior University

The United States Government As Represented by the Department of Veterans Affairs

Trianni, Inc.

Curia IP Holdings, LLC

Brian A Zabel

Eugene C Butcher

Kareem Graham

Jian Zhang

David Park Meininger

Sanjay Malhotra

Vineet Kumar

John A Lippincott

Miao Tan

Justin Monnier

Yayue Zheng

Mallesh Pandrala

Melissa LaJevic

Megha Vaman Rao

Russell K Pachynski

&#x3b1;-NETA analogs are provided for the treatment of inflammatory disease.

Small molecule CMKLR1 antagonists in inflammatory disease

The invention provides novel anti-BTLA antibodies, pharmaceutical compositions comprising such antibodies, and therapeutic methods of using such antibodies and pharmaceutical compositions for the treatment of diseases such as cancer or autoimmune disease.

BTLA-binding antibodies for modulating immune response and treating disease

Chemerin is a chemoattractant that selectively directs intra-tumor recruitment of CMKLR1+ cells. Blockade of CCRL2 from binding to chemerin in non-neoplastic tumor cells, e.g. peri-tumor stromal and/or hematopoietic cells allows for redistribution of chemerin into the tumor and enhanced responsiveness against a tumor.

Methods of enhancing anti-tumor immunity by administering antibodies to the CCRL2 chemerin receptor

Compounds and methods are provided for decreasing demyelinating inflammatory disease in a subject by inhibiting the activity of chemokine-like receptor 1 (CMKLR1). In some embodiments such methods include treating demyelinating inflammatory disease in a subject by administering an agent that antagonizes the activity of chemokine-like receptor 1 (CMKLR1) and/or a CMKLR1 ligand (e.g., chemerin or other endogenous CMKLR1 ligands). Candidate compounds include, without limitation, analogs and variants of 2-(alpha-naphthoyl)ethyltrimethylammonium iodide.

Small molecule CMKLR1 antagonists in demyelinating disease

Methods are provided for decreasing demyelinating inflammatory disease in a subject by inhibiting the activity of chemokine-like receptor 1 (CMKLR1). Methods are also provided for screening for agents that find use in treating demyelinating inflammatory disease in a subject.

Target for regulating multiple sclerosis

Growing community of inventors

Redwood City, CA, United States of America

Brian A Zabel